Acute Kidney Injury Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4517519
  • Report
  • 151 pages
  • P&S Market Research
1 of 3
Acute kidney injury (AKI) or acute kidney failure is a condition characterized by minor or complete loss of kidney function due to a sudden injury to kidneys. AKI is different from chronic kidney disease, wherein the kidney function is lost over a period of time. The disease generally occurs as a complication of another serious disease and is more common in the geriatric population that suffers from various other diseases. The study analyzed that AKI therapeutics pipeline comprises approximately 40 drug candidates in different stages of development.

Insights on Pipeline Segments

According to the research findings, a majority of the drug candidates for the treatment of AKI are being developed to be administered by the intravenous route. It has been observed that the drugs which are being administered through intravenous route have high efficacy because of their higher bioavailability.

AKI Therapeutics Pipeline has been Witnessing Significant Growth due to Increasing Research Funding

Various health organizations such as National Institute of Diabetes and Digestive and Kidney Diseases and Small Business Innovation Research (SBIR) program of the U.S. Small Business Administration (SBA) are strengthening the growth of AKI therapeutics pipeline. For instance, TheraSource LLC received a funding of $335,318 from SBIR for its research project aimed at demonstrating the feasibility of developing recombinant human milk fat globule epidermal growth factor rhMFG E, as a novel and effective therapeutic for treating patients suffering with AKI, associated with ischemia due to low renal perfusion.

Increase in Patents Approval for AKI therapeutics Candidates

There has been an increase in the number of patents approved for the development of drug candidates for the treatment of AKI. For instance, in October 2016, the USPTO issued U.S. Patent 9,464,114 to Arch BioPartners, entitled, “Peptides that Block Leukocyte Recruitment and Methods of Use”. This was the first patent issued protecting the composition and method of use for Metablok.

AKI Therapeutics Pipeline Marked by Various Technological Advancements

Most of the companies are developing innovative technologies for the synthesis or production of drug candidates for the treatment of AKI. For instance, Quark Pharmaceuticals Inc. is using an innovative technology platform for generation of chemically modified siRNA compounds and their delivery to the desired organs. These are particularly well-suited to exploit the potential of siRNA for therapeutic applications. Also, Silver Creek Pharmaceuticals Inc. is using smart growth factor technology platform for the development of growth factors that play an important role in development, maintenance of tissue homeostasis, and pathology of many disease states.

Some of the key players involved in the development of AKI therapeutics include Alloksys Life Sciences B.V., Stealth BioTherapeutics Inc., and Angion Biomedica Corp.
Note: Product cover images may vary from those shown
2 of 3
1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents by industry participant by company type

3. Executive Summary

4. Pipeline Outlook
4.1 Disease Overview
4.1.1 Classification of AKI General classification Classification based on daily urine excretion RIFLE classification system for AKI AKI network classification system
4.2 Causes and Risk Factors
4.2.1 Causes of AKI Reduced blood flow to kidneys Damage to kidneys Obstruction to the drainage of kidneys
4.2.2 Risk Factors of AKI
4.3 Symptoms
4.3.1 Complications
4.4 Diagnosis
4.5 Treatment
4.5.1 Treatment of the Underlying Cause of AKI
4.5.2 Treatment of Symptoms/Complications Associated with AKI
4.6 Prevention
4.7 Epidemiology
4.8 Key Drivers
4.8.1 Research Funding from Various Agencies
4.8.2 No Approved Treatment
4.9 Key Barriers
4.9.1 Discontinuation of Drugs
4.10 Acute Kidney Injury Therapeutics Pipeline Analysis
4.10.1 Pipeline Analysis by Phase
4.10.2 Pipeline Analysis by Molecule Type
4.10.3 Pipeline Analysis by Route of Administration
4.10.4 Pipeline Analysis by Company

5. Acute Kidney Injury Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase III
5.1.1 RESCAP Clinical trials Grant Patents
5.1.2 XX Clinical trials
5.2 Phase II/III
5.2.1 Levosimendan Clinical trials
5.2.2 XX Clinical trials
5.3 Phase II
5.3.1 Elamipretide Collaboration Technology
5.3.2 XX Clinical trials
5.3.3 XX Pre-Clinical results Clinical trials
5.3.4 XX Clinical trials Funding
5.3.5 XX Pre-Clinical results Clinical trials Technology
5.3.6 XX Clinical trials Clinical trial results Pre-Clinical results Funding Strategic developments
5.3.7 XX Clinical trials Clinical trial results Strategic developments
5.3.8 XX Clinical trials
5.4 Phase I/II
5.4.1 SBI-101 Clinical trials Grants
5.5 Phase I
5.5.1 XX Clinical trials Clinical trial results Technology
5.5.2 XX
5.5.3 XX Clinical trials
5.5.4 XX Pre-Clinical result Clinical trials Strategic developments
5.6 IND
5.6.1 XX Pre-Clinical results Patent Technology Strategic developments
5.7 Pre-Clinical
5.7.1 XX Pre-Clinical results Clinical trials Collaboration Patent
5.7.2 XX Technology
5.7.3 XX Technology
5.7.4 XX Strategic developments
5.7.5 XX Pre-Clinical results
5.7.6 XX Strategic developments
5.7.7 XX Pre- Clinical study
5.7.8 XX Pre-Clinical trials Patents Other
5.7.9 XX Pre-Clinical Result
5.7.10 XX Patents Technology Strategic developments
5.7.11 XX Pre-Clinical results Strategic developments
5.7.12 XX Pre-Clinical study
5.7.13 XX Pre-Clinical result
5.7.14 XX Pre-Clinical results Technology
5.7.15 XX
5.7.16 XX Pre-Clinical results
5.7.17 XX Pre-Clinical results
5.7.18 XX Pre-Clinical result
5.8 Discovery
5.8.1 XX
5.8.2 XX Strategic developments
5.8.3 XX Patents
5.9 Unknown
5.9.1 XX Strategic developments

6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status

7. Competitive Landscape
7.1 Key Players Benchmarking for AKI Therapeutics Pipeline
7.2 SWOT Analysis of AKI Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

8. Company Profiles
8.1 Angion Biomedica Corp.
8.1.1 Business Overview
8.1.2 Product & Service Offerings
8.2 Company 2
8.2.1 Business Overview
8.2.2 Product & Service Offerings
8.3 Company 3
8.3.1 Business Overview
8.3.2 Product & Service Offerings
8.4 Company 4
8.4.1 Business Overview
8.4.2 Product & Service Offerings
8.5 Company 5
8.5.1 Business Overview
8.5.2 Product & Service Offerings
8.6 Company 6
8.6.1 Business Overview
8.6.2 Product & Service Offerings
8.7 Company 7
8.7.1 Business Overview
8.7.2 Product & Service Offerings
8.8 Company 8
8.8.1 Business Overview
8.8.2 Product & Service Offerings
8.9 Company 9
8.9.1 Business Overview
8.9.2 Product & Service Offerings
8.1 Company 10
8.10.1 Business Overview
8.10.2 Product & Service Offerings

9. Appendix
9.1 Abbreviations
9.2 Related Reports

List of Tables
Table 1 General Classification of Aki
Table 2 Classification of Aki Based On Daily Urine Excretion
Table 3 Stages of Aki Under Rifle Classification System
Table 4 Stages of Aki Under Akin Classification System
Table 5 Pipeline Analysis of Aki Therapeutics, by Company (2018)
Table 6 Description of Rescap
Table 7 Clinical Trials of Rescap
Table 8 Description of Xx
Table 9 Clinical Trials of Xx
Table 10 Description of Levosimendan
Table 11 Clinical Trials of Levosimendan
Table 12 Description of Xx
Table 13 Clinical Trials of Xx
Table 14 Description of Elamipretide
Table 15 Description of Xx
Table 16 Clinical Trials of Xx
Table 17 Description of Xx
Table 18 Clinical Trials of Xx
Table 19 Description of Xx
Table 20 Clinical Trials of Xx
Table 21 Description of Xx
Table 22 Clinical Trials of Xx
Table 23 Description of Xx
Table 24 Clinical Trials of Xx
Table 25 Description of Xx
Table 26 Clinical Trials of Xx
Table 27 Description of Xx
Table 28 Clinical Trials of Xx
Table 29 Description of Sbi- 101
Table 30 Clinical Trials of Sbi-101
Table 31 Description of Xx
Table 32 Clinical Trials of Xx
Table 33 Description of Xx
Table 34 Description of Xx
Table 35 Clinical Trials of Xx
Table 36 Description of Xx
Table 37 Description of Xx
Table 38 Description of Xx
Table 39 Description of Xx
Table 40 Description of Xx
Table 41 Description of Xx
Table 42 Description of Xx
Table 43 Description of Xx
Table 44 Description of Xx
Table 45 Description of Xx
Table 46 Description of Xx
Table 47 Description of Xx
Table 48 Description of Xx
Table 49 Description of Xx
Table 50 Description of Xx
Table 51 Description of Xx
Table 52 Description of Xx
Table 53 Description of Xx
Table 54 Description of Xx
Table 55 Description of Xx
Table 56 Description of Xx
Table 57 Description of Xx
Table 58 Description of Xx
Table 59 Description of Xx
Table 60 Angion Biomedica Corp. - At a Glance
Table 61 Company 2 - At a Glance
Table 62 Company 3 - At a Glance
Table 63 Company 4 - At a Glance
Table 64 Company 5 - At a Glance
Table 65 Company 6 - At a Glance
Table 66 Company 7 - At a Glance
Table 67 Company 8 - At a Glance
Table 68 Company 9 - At a Glance
Table 69 Company 10 - At a Glance

List of Figures
Fig 1: Research Methodology
Fig 2: Breakdown of Primary Research Respondents, by Industry Participant
Fig 3: Breakdown of Primary Research Respondents, by Company Type
Fig 4: General Classiication of Aki
Fig 5: Clinical Diagnosis of Aki
Fig 6: Treatment Algorithm For Aki
Fig 7: Aki Drug Candidates In Development (2018)
Fig 8: Aki Pipeline Split, by Molecule Type (2018)
Fig 9: Aki Pipeline Split, by Route of Administration (2018)
Fig 10: Breakdown of Clinical Trials, by Region
Fig 11: Breakdown of Clinical Trials, by Trial Status
Fig 12: Key Players Benchmarking
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown